Research Topics
Genomes and GenesSpecies | S LeuchtSummaryAffiliation: Klinikum rechts der Isar Country: Germany Publications
| Collaborators
|
Detail Information
Publications
Is the superior efficacy of new generation antipsychotics an artifact of LOCF?Stefan Leucht
Klinik für Psychiatrie und Psychotherapie der TU München, Klinikum rechts der Isar, Ismaningerstr 22, 81675 Munchen, Germany
Schizophr Bull 33:183-91. 2007..Ultimately, strategies to reduce dropout rates are needed...
Maintenance treatment with antipsychotic drugs for schizophreniaStefan Leucht
Klinik und Poliklinik fur Psychiatrie und Psychotherapie, Technische Universität München Klinikum rechts der Isar, Munchen, Germany
Cochrane Database Syst Rev 5:CD008016. 2012..Antipsychotic drugs block the transmission of dopamine in the brain and reduce the acute symptoms of the disorder. This review examined whether antipsychotic drugs are also effective for relapse prevention...
Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive studyMarc De Hert
University Psychiatric Centre Catholic University Louvain, Leuvensesteenweg 517, 3070 Kortenberg, Belgium
BMC Gastroenterol 11:17. 2011..They also have a number of side-effects. Constipation is thought to be common, and a potential serious side-effect, which has received little attention in recent literature...
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trialsS Leucht
Psychiatrische Klinik, Technischen Universitat Munchen, Klinikum rechts der Isar, Germany
Schizophr Res 35:51-68. 1999..The methodological limitations of this review, the generalizability of the results and expectations from future research are discussed...
Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trialsStefan Leucht
Klinik fr Psychiatrie und Psychotherapie der Technischen Universitt, Ismaningerstr 22, 81675, Muenchen, Germany
Int J Neuropsychopharmacol 7:S15-20. 2004....
Evidence-based pharmacotherapy of schizophreniaStefan Leucht
Department of Psychiatry and Psychotherapy, Technische Universitat Munchen, Klinikum rechts der Isar, Munchen, Germany
Int J Neuropsychopharmacol 14:269-84. 2011..Although the randomized evidence on a superiority of depot compared to oral treatment is not ideal, this approach suggests obvious advantages in assuring compliance...
Second-generation antipsychotics for schizophrenia: can we resolve the conflict?S Leucht
Department of Psychiatry and Psychotherapy, Technische Universitat Munchen, Germany
Psychol Med 39:1591-602. 2009..However, these drugs are important contributions to treatment, and most psychiatrists, let alone patients, would probably not want to do without them...
Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trialsStefan Leucht
Klinik and Poliklinik für Psychiatrie und Psychotherapie der Technichen Universität München, Germany
Am J Psychiatry 160:1209-22. 2003..The authors performed a systematic review and meta-analysis of studies of the potential of new-generation antipsychotic drugs to improve adherence and decrease relapse rates in patients with schizophrenia...
The concepts of remission and recovery in schizophreniaS Leucht
Department of Psychiatry, Technische Universitat Munchen, Munich, Germany
Pharmacopsychiatry 39:161-70. 2006..To examine the past and current research into the concepts of remission and recovery in schizophrenia...
Carbamazepine augmentation for schizophrenia: how good is the evidence?Stefan Leucht
Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universitat Munchen, Germany
J Clin Psychiatry 63:218-24. 2002..The aim of this study was to undertake a systematic review and meta-analysis of the safety and efficacy of one frequently used adjunctive compound: carbamazepine...
Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trialsStefan Leucht
Klinik und Poliklinik fur Psychiatrie und Psychotherapie der Technischen Universitat Munchen, Klinikum rechts der Isar, Munich, Germany
Am J Psychiatry 159:180-90. 2002..The purpose of this article was to compare the atypical profile of amisulpride with that of the 5-HT(2)/D(2) antagonists...
Doxepin plasma concentrations: is there really a therapeutic range?S Leucht
Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universitat Munchen, Gernany
J Clin Psychopharmacol 21:432-9. 2001..Meanwhile, a preliminary working range of 50 to 250 ng/mL is proposed on the basis of critical reassessment of published data...
Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophreniaStefan Leucht
Klinik und Poliklinik fur Psychiatrie und Psychotherapie, Klinikum rechts der Isarder, Technischen Universitat Munchen, Ismaningerstrasse 22, 81675 Munich, Germany
J Clin Psychiatry 67:3-8. 2006..Among the measures that have the potential to improve adherence to medication are psychosocial interventions, psychoeducation in the form of professional, peer-to-peer or family-to-family interventions, and shared decision making...
Clinical implications of Brief Psychiatric Rating Scale scoresStefan Leucht
Klinik fürr Psychiatrie und Psychotherapie derTechnischen Universität München, Klinikum rechts der Isar, Ismaningerstrasse 22, 81675 Munchen, Germany
Br J Psychiatry 187:366-71. 2005..Despite the widespread use of the Brief Psychiatric Rating Scale (BPRS), the clinical meaning of its total score and cut-off values used to define treatment response are unclear...
A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophreniaStefan Leucht
Department of Psychiatry and Psychotherapy, Technische Universitat Munchen, Klinikum rechts der Isar, Ismaningerstr 22, 81675 Munchen, Germany
Am J Psychiatry 166:152-63. 2009..The authors conducted a systematic review and meta-analysis of blinded studies comparing second-generation antipsychotics head-to-head...
Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapyWerner Steimer
Institut fur Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
Clin Chem 51:376-85. 2005..We conducted a prospective blinded two-center study seeking correlations between CYP2C19 and CYP2D6 genotypes, drug concentrations, adverse events, and therapy response...
Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcomeB Laika
Institut fur Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar, Technische Universitat Munchen, Munchen, Deutschland, Germany
Pharmacogenomics J 10:20-9. 2010..Side effects and weight gain, however, seem to be more influenced by serotonergic polymorphisms...
Antidepressants for the negative symptoms of schizophreniaC Rummel
Klinikum rechts der Isar, Klinik und Poliklinik fur Psychiatrie und Psychotherapie der Technischen Universitat Munchen, Möhlstr 26, Munich, Germany 81675
Cochrane Database Syst Rev 3:CD005581. 2006..Negative symptoms are common in people with schizophrenia and are often difficult to treat with antipsychotic drugs. Treatment often involves the use of various add-on medications such as antidepressants...
The effect of family interventions on relapse and rehospitalization in schizophrenia--a meta-analysisG Pitschel-Walz
Department of Psychiatry, Technical University, Munich, Germany
Schizophr Bull 27:73-92. 2001..This meta-analysis indicates that psychoeducational interventions are essential to schizophrenia treatment...
Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapyW Steimer
Institute for Clinical Chemistry and Pathobiochemistry, Munich University of Technology, Ismaninger Str 22, 81675 Munich, Germany
Clin Chim Acta 308:33-41. 2001..Current knowledge in this young field of research is summarized...
Are patients with schizophrenia under-treated with second-generation antipsychotics? A pilot study of the prescription practices of German psychiatristsJ Hamann
Klinik und Poliklinik fur Psychiatrie und Psychotherapie der Technischen Universitat Munchen, Munchen, Germany
Pharmacopsychiatry 36:309-12. 2003..They estimate that only about 10- 30 % of all patients with schizophrenia receive second-generation antipsychotics, a figure that lies significantly below the international average...
Shared decision making for in-patients with schizophreniaJ Hamann
Psychiatric Department, Klinik und Poliklinik fur Psychiatrie und Psychotherapie, Technische Universitat Munchen, Möhlstrasse 26, 81675 Munich, Germany
Acta Psychiatr Scand 114:265-73. 2006..In the present study, the feasibility and effects of SDM for in-patients with schizophrenia should be evaluated...
DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gainJ Popp
Institut fur Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
Pharmacogenomics J 9:71-7. 2009....
Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extendedStefan Leucht
Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany
Biol Psychiatry 57:1543-9. 2005....
Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trialsHarald Scherk
Department of Psychiatry and Psychotherapy, Georg August University Goettingen, Goettingen, Germany
Arch Gen Psychiatry 64:442-55. 2007..Meta-analyses addressing the use of SGAs in the treatment of acute mania are lacking...
[Considerations about the efficacy of psychopharmacological drugs]S Leucht
Klinik und Poliklinik fur Psychiatrie und Psychotherapie, Technische Universitat Munchen, Deutschland
Nervenarzt 82:1425-30. 2011..Psychotropic drugs are efficacious, but they need to be prudently applied according to evidence-based criteria...
Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening?B Laika
Institut fur Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar, Technische Universitat Munchen, Munchen, Germany
Pharmacogenomics J 9:395-403. 2009..Thus, not only poor and ultrarapid metabolizer but also IMs may benefit from CYP2D6 genotyping. This is of paramount interest since it greatly improves cost/benefit estimations for pretreatment CYP2D6 screening...
Language bias in neuroscience--is the Tower of Babel located in Germany?S Heres
Psychiatrische Klinik und Poliklinik, Technischen Universitaet Muenchen, Klinikum rechts der Isar, Ismaningerstrasse 22, Munich 81675, Germany
Eur Psychiatry 19:230-2. 2004..In the neurosciences a similar trend was seen but the findings were not statistically significant. The reason for this inconclusive finding might be the low number of RCTs published in German...
Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trialsAnja Basan
Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universitat Munchen, Ismaninger Str 22, 81675 Munchen, Germany
Schizophr Res 70:33-7. 2004..Some of the single studies showed inconsistent beneficial effects on some aspects of response, but no overall superiority of valproate augmentation at study endpoints was shown...
Linking the PANSS, BPRS, and CGI: clinical implicationsStefan Leucht
Klinik für Psychiatrie und Psychotherapie der TU München, Klinikum rechts der Isar, Munich, Munchen, Germany
Neuropsychopharmacology 31:2318-25. 2006..Clinicians seem to base CGI ratings on relative change rather than on absolute change of symptoms...
Do patients with schizophrenia wish to be involved in decisions about their medical treatment?Johannes Hamann
Klinik und Poliklinik fur Psychiatrie und Psychotherapie, Möhlstrasse 26, 81675 Munchen, Germany
Am J Psychiatry 162:2382-4. 2005..Little is known about the desire of patients with schizophrenia to be involved in medical decisions affecting their treatment...
Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizersWerner Steimer
Institut fur Klinische Chemie und Pathobiochemie, Technische Universitat Munchen, Munich, Germany
Clin Chem 50:1623-33. 2004..These may allow a much desired prediction of metabolic activity within the extensive metabolizer group. The functional consequences are still being discussed with few data available for clinical patients...
What does the PANSS mean?Stefan Leucht
Klinik für Psychiatrie und Psychotherapie der TU München Klinikum rechts der Isar, Ismaningerstr 22, 81675 Munchen, Germany
Schizophr Res 79:231-8. 2005..g. at least 20% or 50% reduction of the baseline score) are as yet unclear. We therefore compared the PANSS with simultaneous ratings of Clinical Global Impressions (CGI)...
Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trialsChristine Rummel
Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universitat Munchen, Möhlstr 26, 81675 Munchen, Germany
Schizophr Res 80:85-97. 2005..The combination of antipsychotics and antidepressants may be more effective in treating negative symptoms of schizophrenia than antipsychotics alone, but this finding needs to be corroborated by further large trials...
How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trialsS Leucht
Department of Psychiatry and Psychotherapy, Klinik für Psychiatrie und Psychotherapie der TU München, Klinikum rechts der Isar, Technische Universitat Munchen, Munchen, Germany
Mol Psychiatry 14:429-47. 2009..Whether methodological issues account in part for the relatively low efficacy ESs and the scarcity of adverse event differences compared with placebo needs to be established...
Shared decision making in psychiatryJ Hamann
Department of Psychiatry and Psychotherapy, Center for Disease Management, Technical University Munich, Germany
Acta Psychiatr Scand 107:403-9. 2003..In other medical fields, 'shared decision making' (a strategy for including patients in therapeutic decision processes) has been studied for several years now. This survey presents the potential of shared decision making for psychiatry...
Shared decision making and long-term outcome in schizophrenia treatmentJohannes Hamann
Department of Psychiatry, Technische Universitat, Munich, Germany
J Clin Psychiatry 68:992-7. 2007..The aim of the present analysis was to study whether shared decision making (SDM) in antipsychotic drug choice would influence long-term outcome...
Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine studyStefan Leucht
Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universitat Munchen, Ismaningerstr 22, 81675 Munchen, Germany
Schizophr Res 101:312-9. 2008..To use the degree of response after 2 weeks of treatment to predict non-response at 4 to 6 weeks...
Physicians' and patients' involvement in relapse prevention with antipsychotics in schizophreniaJohannes Hamann
Psychiatry Department, Technische Universitat Munchen, Germany
Psychiatr Serv 56:1448-50. 2005..Accordingly, patients' knowledge of the optimal duration of maintenance therapy was poor...
The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trialsStefan Leucht
Klinik für Psychiatrie und Psychotherapie der TU München, Klinikum rechts der Isar, Germany
Neuropsychopharmacology 31:406-12. 2006..The fact that it takes only 1-2 min to fill in the CGI justifies its use in addition to more specific scales in drug trials for schizophrenia. Further development and evaluation of the CGI is warranted...
Early prediction of antipsychotic nonresponse among patients with schizophreniaStefan Leucht
Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universitat Munchen, Germany
J Clin Psychiatry 68:352-60. 2007..We therefore attempted to identify what degree of nonresponse shortly after initiation of antipsychotic drug treatment predicts nonresponse at 4 weeks...
Olanzapine versus other atypical antipsychotics for schizophreniaKatja Komossa
, , Moehlstrasse 26, , Germany, 81675
Cochrane Database Syst Rev 3:CD006654. 2010..Further large, well-designed trials are necessary to establish the relative effects of different second generation antipsychotic drugs...
European psychiatric treatment guidelines: is the glass half full or half empty?M Stiegler
Department of Psychiatry and Psychotherapy, Technische Universitat Munchen, Ismaningerstr 22, 81675 Munich, Germany
Eur Psychiatry 20:554-8. 2005..The main focus was the question of whether the development process of the guidelines followed basic principles of evidence-based medicine...
How to read and understand and use systematic reviews and meta-analysesS Leucht
Klinik and Poliklinik für Psychiatrie and Psychotherapie, Technische Universitat Munchen, Munchen, Germany
Acta Psychiatr Scand 119:443-50. 2009..Systematic reviews and meta-analyses are increasingly frequently used in the evaluation of medical treatments. This review explains the principles of the methodology, significance and limitations of systematic reviews...
On the concept of remission in schizophreniaStefan Leucht
Department of Psychiatry and Psychotherapy, Technische Universitat Munchen, Klinikum rechts der Isar, Ismaningerstr 22, 81675, Munich, Germany
Psychopharmacology (Berl) 194:453-61. 2007..Criteria for remission in schizophrenia have recently been presented. It is unclear how many acutely ill patients meet these criteria and how they compare with previously suggested definitions...
The attitude of patients towards antipsychotic depot treatmentStephan Heres
Klinik und Poliklinik fur Psychiatrie und Psychotherapie, Technical University Munich, am Klinikum rechts der Isar, Moehlstrasse 26, D 81675 Munich, Germany
Int Clin Psychopharmacol 22:275-82. 2007..A considerable number of patients would accept a depot drug as a long-term treatment option. The gap between patients' acceptance and the low prescription rates can be narrowed by offering antipsychotic depots to more patients...
Measurement-based psychiatry: definitions of response, remission, stability, and relapse in schizophreniaStefan Leucht
, , Klinikum rechts der Isar, Munich, Germany
J Clin Psychiatry 67:1813-4. 2006
Attitudes of psychiatrists toward antipsychotic depot medicationStephan Heres
Klinik und Poliklinik fuer Psychiatrie und Psychotherapie der Technischen, Universitaet Muenchen am Klinikum rechts der, Muenchen, Germany
J Clin Psychiatry 67:1948-53. 2006..Nevertheless, long-acting injectable formulations are seldom prescribed in the treatment of schizophrenia...
Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffsStefan Leucht
Department of Psychiatry and Psychotherapy, Technische Universitat Munchen, Klinikum rechts der Isar, Ismaningerstrasse 22, 81675 Munich, Germany
Neuropsychopharmacology 32:1903-10. 2007..We suggest a table presenting responder rates in 25 percent steps covering the whole range up to 100% reduction from baseline, which could be displayed together with recently presented criteria for remission...
Comparative remission rates of schizophrenic patients using various remission criteriaRomain Beitinger
Department of Psychiatry and Psychotherapy, Technische Universitat Munchen, Klinikum rechts der Isar, Möhlstr 28, 81675 Munich, Germany
Prog Neuropsychopharmacol Biol Psychiatry 32:1643-51. 2008..New standardized criteria for remission in schizophrenia were presented in 2005 which need to be examined in regard to their significance for clinical trials...
New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysisStefan Leucht
Klinik und Poliklinik fur Psychiatrie und Psychotherapie der Technischen Universitat Munchen, Klinikum rechts der Isar, Munchen, Germany
Lancet 361:1581-9. 2003..We aimed to establish whether the new drugs induce fewer EPS than low-potency conventional antipsychotics...
Physical illness and schizophrenia: a review of the literatureS Leucht
Klinik für Psychiatrie und Psychotherapie der TU München, Klinikum rechts der Isar, Ismaningerstr, Munchen, Germany
Acta Psychiatr Scand 116:317-33. 2007..The lifespan of people with schizophrenia is shortened compared to the general population. We reviewed the literature on comorbid physical diseases in schizophrenia to provide a basis for initiatives to fight this unacceptable situation...
Medical decision making in antipsychotic drug choice for schizophreniaJohannes Hamann
Psychiatric Department, Technical University of Munich, Möhlstrasse 26, 81675 Munich, Germany
Am J Psychiatry 161:1301-4. 2004..The influence of patient and physician variables on antipsychotic drug choice for patients with schizophrenia was assessed...
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysisStefan Leucht
Department of Psychiatry and Psychotherapy, Technische Universitat Munchen, Munich, Germany
Lancet 373:31-41. 2009....
How do psychiatrists choose among different antipsychotics?Johannes Hamann
Department for Psychiatry and Psychotherapy, Technische Universitat, Möhlstrasse 26, 81675 Munich, Germany
Eur J Clin Pharmacol 61:851-4. 2005..We attempted to determine the decision rules psychiatrists use in the choice of antipsychotic drugs for inpatients with schizophrenia...
Amisulpride is an "atypical" antipsychotic associated with low weight gainStefan Leucht
Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universitat Munchen, Ismaningerstrasse 22, 81675 Munich, Germany
Psychopharmacology (Berl) 173:112-5. 2004..While most "atypicals" have a high affinity for both dopamine and serotonin receptors, amisulpride has only dopamine receptor action...
Translating research into clinical practice: critical interpretation of clinical trials in schizophreniaStefan Leucht
Klinik und Poliklinik fur Psychiatrie und Psychotherapie, Technische Universität München Klinikum rechts der Isar, Ismaningerstrasse 22, 81675 Munich, Germany
Int Clin Psychopharmacol 21:S1-10. 2006..Better training of clinicians in the interpretation of scientific results and the use of more meaningful clinical outcomes are both needed to effectively translate research into clinical practice...
Serotonin transporter polymorphisms and side effects in antidepressant therapy--a pilot studyJohannes Popp
Technische Universitat Munchen, Institut fur Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar Ismaninger Str 22 81675 München, Germany
Pharmacogenomics 7:159-66. 2006....
Methodological issues in current antipsychotic drug trialsStefan Leucht
Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universitat Munchen, Ismaningerstr 22, 81675 Munchen, Germany
Schizophr Bull 34:275-85. 2008..The authors present practical examples to highlight the current problems and propose a concrete series of suggestions on how to further optimize antipsychotic drug trials in the future...
Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomesSusanne Rösner
IFT, Institut für Therapieforschung, Munich, Germany
J Psychopharmacol 22:11-23. 2008..Benefits in the treatment of alcohol dependence might be optimized by matching the efficacy profiles of specific antidipsotropics with the motivational status of alcohol-dependent patients...
Psychiatric decision making in the adoption of a new antipsychotic in GermanyJohannes Hamann
Technische Universitat Munchen, Möhlstrasse 26, Muenchen, Germany 81675
Psychiatr Serv 57:700-3. 2006..Studies in somatic medicine have demonstrated delays in the implementation of new drugs, but data on psychiatric drugs are scarce. This study examined psychiatrists' adoption of a new antipsychotic...
How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed?Johannes Hamann
Klinik und Poliklinik fur Psychiatrie und Psychotherapie, Technische Universitat Munchen, Germany
Eur Neuropsychopharmacol 20:276-9. 2010..Other psychiatrist-related factors (e.g. age, gender, and work experience) did not influence attitudes toward depot...
Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trialsStefan Leucht
Zucker Hillside Hospital, Glen Oaks, N Y, USA
J Clin Psychiatry 65:177-86. 2004..Clinicians frequently use lithium to augment antipsychotic medication in schizophrenia. Therefore, we undertook a systematic review and meta-analysis of the use of lithium in the treatment of schizophrenia...
Pretrial medication bias in randomized antipsychotic drug trialsStefan Leucht
Am J Psychiatry 164:1266; author reply 1266-7. 2007
Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGIStephen Z Levine
Bar Ilan University, Ramat Gan 52900, Israel
Schizophr Res 98:318-22. 2008..This research has not been replicated nor examined in individual trials. This study aims to examine the feasibility of extrapolation from the CGI to the PANSS across and within 4 large clinical trials of antipsychotic medication...
Relationship between costs and symptoms in schizophrenia patients treated with antipsychotic medication: a reviewSerge Sevy
Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
J Clin Psychiatry 65:756-65. 2004..The purpose of this review is to understand how changes in costs of illness are related to the effects of antipsychotic medications on symptoms in schizophrenia patients...
ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptylineBarbara Laika
Clin Chem 52:893-5. 2006
Unanswered questions in schizophrenia clinical trialsJohn M Kane
The Zucker Hillside Hospital, Glen Oaks, New York, NY, USA
Schizophr Bull 34:302-9. 2008
Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychoticsStephan Heres
Klinik und Poliklinik für Psychiatrie und Psychotherapie der Technischen Universität München am Klinikum rechts der Isar, Moehlstrasse 26, 81675 Munich, Germany
Am J Psychiatry 163:185-94. 2006....
Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studiesChristoph U Correll
Department of Psychiatry Research, Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Schneider Children s Hospital, Glen Oaks, NY 11004, USA
Am J Psychiatry 161:414-25. 2004..This hypothesis was examined in a systematic review of studies involving open or controlled treatment with any second-generation antipsychotic...
Medical decision making in the mental health fieldJohannes Hamann
Psychiatr Serv 56:221. 2005
Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over timeThomas A Trikalinos
Institute for Clinical Care Research and Health Policy Studies, Tufts-New England Medical Center, Tufts University School of Medicine, Boston, MA, USA
J Clin Epidemiol 57:1124-30. 2004..51, P = .009). CONCLUSIONS: Evidence based on a small number of randomized subjects should be interpreted cautiously. Early treatment efficacy of pharmacotherapies is occasionally overestimated...
The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summaryJohn M Kane
J Clin Psychiatry 64:5-19. 2003....
Commentary on strategies for switching antipsychoticsJohn M Davis
Department of Psychiatry, University of Illinois at Chicago, 1601 West Taylor Street, Chicago, IL 60612, USA
BMC Med 6:18. 2008..In this issue, Ganguli et al. have carried out a randomized switching study, the data from which indicates the tactics that might be optimal. We put this paper into context, provide a critique and describe indications for switching...
Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challengesW Wolfgang Fleischhacker
Department of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria
J Clin Psychiatry 69:514-9. 2008....
Has research informed us on the practical drug treatment of schizophrenia?John M Davis
Schizophr Bull 34:403-5. 2008
Issues in psychopharmacologyJohn M Kane
The Zucker Hillside Hospital Glen Oaks, New York, NY, USA
Schizophr Bull 34:258. 2008
Cochrane Schizophrenia GroupClive E Adams
Division of Psychiatry, University of Nottingham, UK
Schizophr Bull 34:259-65. 2008
